A. de Nonneville, A. Gonçalves
Oncologie, Vol.21, No.1, pp. 33-39, 2019, DOI:10.3166/onco-2019-0039
Abstract Triple-negative breast cancer (TNBC), defined by
the lack of expression of hormone receptors and HER2
(Human Epidermal growth factor Receptor-2), accounts for
15–20% of breast cancers. However, this definition, which is
essentially negative, masks the large biological heterogeneity of this subtype. While chemotherapy is the main established systemic treatment in both early and advanced stages
of the disease, the progressive understanding of the molecular components involved in the pathogenesis of TNBC
allows innovative therapeutic perspectives. The objective
of this review is to describe these potential targets and to
explore current and future treatments that will help fighting
this cancer with… More >
Login
Register
